Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Clinical trial NCT05617313 · TERMINATED

Trial details

NCT number: NCT05617313
Sponsor: Jeffrey Clarke
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer Metastatic NSCLC Recurrent Non Small Cell Lung Cancer

Start date: 2023-02-17
Primary completion: 2025-06-26
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.